

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Koselugo Prior Authorization Policy

- Koselugo<sup>™</sup> (selumetinib capsules – AstraZeneca)

**REVIEW DATE:** 04/10/2024

---

### OVERVIEW

Koselugo, a kinase inhibitor, is indicated for the treatment of **neurofibromatosis type 1** (NF1) in patients  $\geq 2$  years of age with who have symptomatic, inoperable plexiform neurofibromas.<sup>1</sup>

Koselugo is a mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) inhibitor.<sup>1</sup>

### Disease Overview

Neurofibromatoses are a group of tumor suppressor syndromes that predisposes patients to an increased risk of nervous system tumors including neurofibromas, malignant peripheral nerve sheath tumors, and gliomas.<sup>5,6</sup> NF1 is the most common of the neurofibromatoses, occurring in approximately one in 2,500 to 3,000 individuals worldwide.<sup>7,8</sup> NF1 is an autosomal dominant disorder, with 50% of children of affected parents inheriting the mutated NF1 tumor-suppressor gene.<sup>5,7</sup> However, up to 50% of the cases occur spontaneously in patients without a family of NF1.<sup>5-9</sup>

Plexiform neurofibromas are benign nerve sheath tumors that can occur anywhere in the body,<sup>8</sup> affect up to 50% of patients with NF1,<sup>5</sup> and are often present at birth.<sup>7,8</sup> These tumors tend to grow the fastest in the first decade of life,<sup>7,8</sup> and can continue to grow into adolescence and early adulthood.<sup>7</sup> Plexiform neurofibromas may be asymptomatic and only detected with MRI,<sup>5,8</sup> or may cause significant pain,<sup>5,7</sup> disfigurement,<sup>5</sup> bone destruction,<sup>7</sup> and loss of nerve function.<sup>5</sup> Due to the risk of transformation to malignant peripheral nerve sheath tumors, patients with any change in the signs or symptoms of plexiform neurofibromas should be assessed for malignant transformation.<sup>5,8</sup>

### Other Uses with Supportive Evidence

In a Phase II, open-label trial, the efficacy of Koselugo was assessed in patients 3 to 21 years of age with recurrent, refractory, or progressive pilocytic astrocytoma with either *KIAA1549-BRAF* fusion or *BRAF V600E* mutation.<sup>2</sup> Koselugo 25 mg/m<sup>2</sup>/dose was administered twice daily for up to 2 years if the patient did not have progressive disease or unacceptable adverse events. A total of 25 patients were enrolled with a median age of 9.2 years, and 52% were female. A partial response was achieved in 36% of patients, 36% of patients had stable disease, and 28% had disease progression. The 2 year progression-free survival was 70% and 44% of patients have not progressed after a median of 36.4 months of follow-up.

### Guidelines

Koselugo is addressed in National Comprehensive Cancer Network (NCCN) guidelines:

- **Central nervous system cancers:** Clinical practice guidelines (version 1.2023 – March 24, 2023) recommend Koselugo for the treatment of recurrent or progressive circumscribed glioma with *BRAF* fusion or *BRAF V600E* activating mutation positive; or neurofibromatosis type 1 mutated glioma, as a single agent.<sup>3,4</sup>
- **Histiocytic Neoplasms:** Clinical practice guidelines (version 1.2024 – March 15, 2024) recommend Koselugo as a single agent for the first-line or subsequent treatment of mitogen-activated protein kinase pathway mutation, no detectable mutation, or testing not available for

04/10/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

multisystem Langerhans cell histiocytosis (LCH), single-system lung LCH, multifocal (> 2 lesions) single system bone LCH not responsive to a bisphosphonate, and central nervous system LCH.<sup>10</sup>

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Koselugo. All approvals are provided for the duration noted below.

**Automation:** None.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Koselugo is recommended in those who meet the following criteria:

### FDA-Approved Indication

1. **Neurofibromatosis Type 1.** Approve for 1 year if the patient meets ALL of the following (A and B):
  - A) Patient meets ONE of the following (i or ii):
    - i. Patient is 2 to 18 years of age; OR
    - ii. Patient meets BOTH of the following (a and b):
      - a) Patient is  $\geq 19$  years of age; AND
      - b) Patient has been previously started on therapy with Koselugo prior to becoming 19 years of age; AND
  - B) Prior to starting Koselugo, the patient had symptomatic, inoperable plexiform neurofibromas, according to the prescriber.

### Other Uses with Supportive Evidence

2. **Circumscribed Glioma.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):
  - A) Patient meets ONE of the following (i or ii):
    - i. Patient is 3 to 21 years of age; OR
    - ii. Patient meets BOTH of the following (a and b):
      - a) Patient is > 21 years of age; AND
      - b) Patient has been previously started on therapy with Koselugo prior to becoming 21 years of age; AND
  - B) Patient has recurrent, refractory, or progressive disease; AND
  - C) Tumor meets ONE of the following (i, ii, or iii):
    - i. Tumor is *BRAF* fusion positive; OR
    - ii. Tumor is *BRAF V600E* activating mutation positive; OR
    - iii. Patient has neurofibromatosis type 1 mutated glioma; AND
  - D) The medication will be used as a single agent.
3. **Langerhans Cell Histiocytosis.** Approve for 1 year if the patient meets ALL of the following (A and B):
  - A) Patient meets ONE of the following (i, ii, iii, or iv):
    - i. Patient meets BOTH of the following (a and b):
      - a) Patient has multisystem Langerhans cell histiocytosis; AND
      - b) Patient has symptomatic disease or impending organ dysfunction; OR
    - ii. Patient has single system lung Langerhans cell histiocytosis; OR

- iii. Patient meets ALL of the following (a, b, and c):
  - a) Patient has single system bone disease; AND
  - b) Patient has not responded to treatment with a bisphosphonate; AND  
Note: Examples of bisphosphonates include pamidronate and zoledronic acid.
  - c) Patient has more than 2 bone lesions; OR
- iv. Patient has central nervous system disease; AND
- B) The medication is used as a single agent.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Koselugo is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Koselugo™ capsules [prescribing information]. Wilmington, DE: AstraZeneca; January 2024.
2. Fangusaro J, Onar-Thomas A, Poussaint TY, et al. Selumetinib in children with *BRAF*-aberrant or neurofibromatosis type 1-associated recurrent, refractory or progressive low-grade glioma: a multi-center Phase II trial. *Lancet Oncol*. 2019;20:1011-1022.
3. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 1, 2024. Search term: selumetinib.
4. The NCCN Central Nervous System Cancers Clinical Practice Guidelines in Oncology (version 1.2023 – March 24, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on: April 1, 2024.
5. US National Institute of Health. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2020 March 23]. Available at: <https://clinicaltrials.gov/ct2/results?cond=&term=selumetinib&cntry=&state=&city=&dist=>. Search term: selumetinib.
6. Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. *Med Clin N Am*. 2019;103:1035-1054.
7. Plotkin SR, Wick A. Neurofibromatosis and Schwannomatosis. *Semin Neurol*. 2018;38:73-85.
8. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: A multidisciplinary approach to care. *Lancet Neurol*. 2014;13:834-843.
9. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. *Handb Clin Neurol*. 2018;148:799-811.
10. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (version 1.2024 – March 15, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on: April 1, 2024.